Sponsors, CROs and academic research teams choosing an eCOA platform for a regulated clinical trial.
Scope Electronic clinical outcome assessment (eCOA) platforms that capture patient-reported (ePRO), clinician-reported, observer-reported and performance outcomes in regulated clinical trials, as a sponsor, CRO or academic research team would shortlist them.
These notes describe the products in the eCOA guide.
Clario
Best for
Global pivotal trials that combine eCOA with cardiac, respiratory, imaging or sensor endpoints
What to consider
Clario has the deepest enterprise eCOA profile here: studies in 120+ countries and 100+ languages, a named eCOA science team and pre-validated assessment libraries. It says it has supported 70% of FDA and EMA new drug approvals since 2015 across its endpoints. Builds are delivered by Clario and prices are not published.
CNS and other complex-endpoint trials that need clinician ratings, licensing support and global logistics
What to consider
Signant combines a 50+ instrument library, in-house licensing support and 50+ clinical and eCOA experts with operations in 135+ countries. It says it supported 25% of FDA and EMA novel drug approvals from 2020 to 2025 and now adds wearable sensors through Ametris. Builds are vendor-led and prices are not published.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Clario vs Signant eCOA (eCOA): category feature evidence and sources. Products are not ranked.
Category feature
Clario
Signant eCOA
Validated instrument library and licensingFeature definitions
Supported
A library of outcome-assessment instruments is documented.
Extended support
A validated or instrument-author-approved library plus managed instrument licensing are documented.
Clario
Supported
Pre-built, validated assessment libraries, the Rapid Start assessment catalog and an eCOA Science Services team with named scientists.
The library includes author-approved instruments with scale licensing and management support.
Regulatory compliance and track recordFeature definitions
Supported
Relevant trial or security controls are stated.
Extended support
Relevant trial controls plus a public ISO/SOC certificate or audit report are documented; a certification claim or logo alone is insufficient.
Clario
Supported
States it has supported 70% of FDA and EMA new drug approvals since 2015 (company-wide, all endpoint types); ISO 27001:2022 and SOC 2 Type II are published separately.
BYOD, provisioned capture and wearable sensors are listed; sensor integration is not established by this note.
Time to launch and self-service buildFeature definitions
Supported
A study build process, self-service builder or launch timeframe is documented.
Extended support
Study teams can configure the study themselves, with a stated build or launch timeframe.
Clario
Supported
eCOA Swift deploys early-phase oncology trials in as little as 2 weeks and Rapid Start offers pre-configured assessments; builds are vendor-delivered, no self-service designer published.